Skip to main content

Advertisement

SpringerLink
Log in

EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The purposes of this study were to assess the levels of symptom distress, body image, and epidermal growth factor receptor inhibitors (EGFRI)-associated health-related quality of life (QoL); identify the factors related to EGFRI-associated health-related QoL; and examine the differences in EGFRI-associated health-related QoL by grade of skin toxicity in mCRC patients receiving target therapy.

Methods

This cross-sectional study examined mCRC patients who received cetuximab-based target therapy from the oncology and CRC inpatient and outpatient departments of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ symptom distress, body image, and EGFRI-associated health-related QoL.

Results

Of the 111 mCRC patients studied, 79.2% reported acneiform eruption and 52.2% reported paronychia. The most common symptoms were dry skin and itching. Poor EGFRI-associated health-related QoL was associated with more symptom distress, more negative body image, a higher cumulative dose of target therapy, and being married; these factors explained 66.6% of the variance in EGFRI-associated health-related QoL.

Conclusion

Patient-specific skin care and emotional support are needed to relieve distressful dermatological symptoms and emotional distress during and post-treatment for mCRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International agency for research on cancer (2019) Cancer fact sheets: colorectal cancer. Available from: https://gco.iarc.fr/today/fact-sheets-cancers? cancer=6&type=0&sex=0. Ministry of Health Welfare, Taiwan, ROC. 2017 statistics cause of death. Available from: http://www.doh.gov.tw. Accessed May 16, 2019

  2. Taiwan cancer registry (2019) 2018 Annual Report. Available from: http://crs.cph.ntu.edu.tw/. Accessed May 16, 2019

  3. Berretta M, Alessandrini L, De Divitiis C et al (2017) Serum and tissue markers in colorectal cancer: state of art. Crit Rev Oncol Hematol 111:103–116. https://doi.org/10.1016/j.critrevonc.2017.01.007

    Article  PubMed  Google Scholar 

  4. Stulhofer Buzina D, Martinac I, Ledic Drvar D et al (2016) Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croati 24:70–72

    Google Scholar 

  5. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176

    Article  CAS  Google Scholar 

  6. D'Alessio A, Cecchini S, Di Mauro D et al (2016) Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Tumori 102. https://doi.org/10.5301/tj.5000579

  7. Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456. https://doi.org/10.1093/annonc/mdj084

    Article  CAS  PubMed  Google Scholar 

  8. Giuliani J, Marzola M (2013) Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor? J Gastrointest Cancer 44:241–345. https://doi.org/10.1007/s12029-013-9485-7

    Article  CAS  PubMed  Google Scholar 

  9. Takada S, Sagawa T, Fujikawa K, Tahatsu K, Fukai Y, Hashishita H, Takahashi Y, Endo M (2018) Skin disorders and primary tumor location as prognostic factors in patients with metastatic colorectal cancer treated with cetuximab and chemotherapy. Asian Pac J Cancer Prev 19:2325–2330. https://doi.org/10.22034/APJCP.2018.19.8.2325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, Cui H (2019) Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends 12:537–552. https://doi.org/10.5582/bst.2018.01246

    Article  CAS  PubMed  Google Scholar 

  11. Charalambous A, Charalambous M (2016) “I lost my image, the image others know me by”: findings from a hermeneutic phenomenological study of patients living with treatment-induced cutaneous toxicities. Res Nurs Health 39:187–196. https://doi.org/10.1002/nur.21722

    Article  PubMed  Google Scholar 

  12. Charles C, Razavi D, Bungener C, Mateus C, Lanoy E, Verschoore M, Dauchy S, Robert C (2016) Impact of skin toxicities associated with targeted cancer therapies on body image: a prospective study. Clin Drug Investig 36:235–242. https://doi.org/10.1007/s40261-015-0373-8

    Article  CAS  PubMed  Google Scholar 

  13. De Tursi M, Zilli M, Carella C et al (2017) Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. OncoTargets Ther 16:3007–3015. https://doi.org/10.2147/OTT.S127795 eCollection 2017

    Article  Google Scholar 

  14. Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159

    Article  CAS  Google Scholar 

  15. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic. Cancer 1:634–656

    Article  Google Scholar 

  16. National comprehensive cancer network (2018) NCCN guidelines for patients: colon cancers 2018. Available From: http://www.nccn.org. Accessed May 16, 2019

  17. McCorkle R, Young K (1978) Development of symptom distress scale. Cancer Nurs 1:373–378

    Article  CAS  Google Scholar 

  18. Veale D, Eshkevari E, Kanakam N, Ellison N, Costa A, Werner T (2014) The appearance anxiety inventory: validation of a process measure in the treatment of body dysmorphic disorder. Behav Cogn Psychother 42:605–616. https://doi.org/10.1017/S1352465813000556

    Article  PubMed  Google Scholar 

  19. Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21:1033–1041. https://doi.org/10.1007/s00520-012-1623-4

    Article  PubMed  Google Scholar 

  20. National cancer institute (2010) Common terminology criteria for adverse events (CTCAE), Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed May 16, 2019

  21. Bonomo P, Loi M, Desideri I et al (2017) Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review. Crit Rev Oncol Hematol 120:98–110. https://doi.org/10.1016/j.critrevonc.2017.10.011

    Article  PubMed  Google Scholar 

  22. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357. https://doi.org/10.1200/JCO.2008.21.7828

    Article  CAS  PubMed  Google Scholar 

  23. Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 8:509–522. https://doi.org/10.1007/s00520-009-0744-x

    Article  Google Scholar 

  24. Fitzpatrick TB (1975) Sun and skin. Journal de Médecine Esthétique [in French] 2:33–34

    Google Scholar 

  25. Australian Radiation Protection and Nuclear Safety Agency (2007) Fitzpatrick skin phenotype. Available from: https://www.arpansa.gov.au/sites/default/files/legacy/pubs/RadiationProtection/FitzpatrickSkinType.pdf. Accessed May 16, 2019

  26. Chan MWM, Shek SY, Yeung CK, Chan HH (2019) A prospective study in the treatment of lentigines in Asian skin using 532 nm picosecond Nd:YAG laser. Lasers Surg Med 51:767–773

    Article  Google Scholar 

  27. Jo HC, Kim DY (2019) Correlation between light absorbance and skin color using fabricated skin phantoms with different colors. Lasers Med Sci 1–8. https://doi.org/10.1007/s10103-019-02888-0

  28. Chang YL, Huang BS, Hung TM, Lin CY, Chen SC (2019) Factors influencing body image in posttreatment oral cavity cancer patients. Psychooncology 28:1127–1133. https://doi.org/10.1002/pon.5067

    Article  PubMed  Google Scholar 

  29. Chen SC, Huang BS, Hung TM et al (2019) Impact of a behavior change program and health education on social interactions in survivors of head and neck cancer: randomized controlled trial. Psychooncology 28:293–300. https://doi.org/10.1002/pon.4939

    Article  PubMed  Google Scholar 

  30. Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH (2012) Skin toxicity and quality of life in patients with metastatic cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12:438. https://doi.org/10.1186/1471-2407-12-438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dahlhoff M, Frances D, Kloepper JE, Paus R, Schäfer M, Niemann C, Schneider MR (2014) Overexpression of epigen during embryonic development induces reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia. Mol Cell Biol 34:3086–3095. https://doi.org/10.1128/MCB.00302-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812

    Article  CAS  Google Scholar 

  33. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845–851

    Article  CAS  Google Scholar 

  34. Esser P, Mehnert A, Johansen C, Hornemann B, Dietz A, Ernst J (2018) Body image mediates the effect of cancer-related stigmatization on depression: a new target for intervention. Psychooncology 27:193–198. https://doi.org/10.1002/pon.4494

    Article  PubMed  Google Scholar 

  35. Phelan SM, Griffin JM, Jackson GL, Zafar SY, Hellerstedt W, Stahre M, Nelson D, Zullig LL, Burgess DJ, van Ryn M (2013) Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. Psychooncology 22:65–73. https://doi.org/10.1002/pon.2048

    Article  PubMed  Google Scholar 

  36. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327–333. https://doi.org/10.1007/s40257-013-0021-0

    Article  PubMed  Google Scholar 

  37. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916–3923. https://doi.org/10.1002/cncr.25090

    Article  PubMed  Google Scholar 

  38. Stanculeanu DL, Zob D, Toma OC, Georgescu B, Papagheorghe L, Mihaila RI (2017) Cutaneous toxicities of molecular targeted therapies. Maedica (Buchar) 12:48–54

    Google Scholar 

  39. Lee JJ, Kroshinsky D, Hoang MP (2017) Cutaneous reactions to targeted therapy. Am J Dermatopathol 39:67–82. https://doi.org/10.1097/DAD.0000000000000504

    Article  PubMed  Google Scholar 

  40. Davidson A, Williams J (2019) Factors affecting quality of life in patients experiencing facial disfigurement due to surgery for head and neck cancer. Br J Nurs 28:180–184. https://doi.org/10.12968/bjon.2019.28.3.180

    Article  PubMed  Google Scholar 

  41. Hirpara DH, Azin A, Mulcahy V et al (2019) The impact of surgical modality on self-reported body image, quality of life and survivorship after anterior resection for colorectal cancer–a mixed methods study. Can J Surg 62:1–8. https://doi.org/10.1503/cjs.014717

    Article  Google Scholar 

  42. Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven K, Kaptein AA (2016) Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 24:513–521. https://doi.org/10.1007/s00520-015-2781-y

    Article  PubMed  Google Scholar 

  43. Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, Seite S, Dreno B (2013) Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res 5:401–408. https://doi.org/10.2147/CMAR.S52256 eCollection 2013

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the patients who participated in the study. The authors also thank Convergence CT for the assistance of English editing.

Funding

Chang Gung Memorial Hospital, Grant/Award Number: CMRPG3G1591.

This study was supported by grant from Chang Gung Memorial Hospital (CMRPG3G1591) Research Program in Taiwan.

Author information

Author notes

  1. Sui-Whi Jane and Shu-Ching Chen contributed equally to this work.

Authors and Affiliations

  1. Department of Nursing, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

    Ting-Yu Chiang

  2. Division of Hematology/Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

    Hung-Chih Hsu

  3. College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Hung-Chih Hsu

  4. School of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan

    Sui-Whi Jane & Shu-Ching Chen

  5. Division of Hematology/Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

    Sui-Whi Jane

  6. School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Sui-Whi Jane & Shu-Ching Chen

  7. Geriatric and Long-Term Care Research Center, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan

    Sui-Whi Jane & Shu-Ching Chen

  8. Department of Radiation Oncology and Proton and Radiation Therapy Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

    Shu-Ching Chen

Authors
  1. Ting-Yu Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hung-Chih Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sui-Whi Jane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu-Ching Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shu-Ching Chen.

Ethics declarations

The study was approved by the Institutional Review Board of Chang Gung Medical Foundation Institutional Review Board in Taiwan, and a permission certificate was obtained (Number: 201701198B0).

Conflict of interest

The authors declare that they have no competing interests.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiang, TY., Hsu, HC., Jane, SW. et al. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy. Support Care Cancer 28, 4771–4779 (2020). https://doi.org/10.1007/s00520-020-05321-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05321-3

Keywords

Search

Navigation